Organometallic Ligands

Please enquire for more information about HKI 357 including the price, delivery time and more detailed product information at the technical inquiry form on this page

SLF-100 is an enzymatic solution, which is derived from a consortium of beneficial microorganisms. This product functions by breaking down organic matter and releasing bound nutrients within the soil, thus enhancing nutrient availability and promoting plant health. The action of SLF-100 is mediated primarily by its enzymatic components, which include cellulase, amylase, and protease, among others. These enzymes work synergistically to degrade complex organic compounds, facilitating the release of macro and micronutrients.

(4bS,8aS,9S,10S)-10-(Acetyloxy)-3,9-bis(benzoyloxy)-4b,5,6,7,8,8a,9,10-octahydro-4b,8,8-trimethyl-2-(1-methylethyl)-1,4-phenanthrene dione is a potent chemokine molecule that is an agonist of the CXCR2 receptor. It has been shown to inhibit cancer stem cells and chemoattractant production in colon carcinoma cells. This compound selectively targets the translation of lamiaceae mRNA and induces apoptosis in colon carcinoma cells.

Anandamide - d4 is a stable isotope-labeled analog of anandamide, which is an endocannabinoid naturally occurring in the human body. This particular compound is synthesized, allowing for precise structural modifications while providing a stable isotopic label, deuterium. Anandamide - d4 interacts with the cannabinoid receptors, CB1 and CB2, mimicking the biological activities of endogenous anandamide but allowing for enhanced traceability in analytical studies.

Pyr10 is an advanced catalytic agent, which is derived from modified zeolitic materials with high thermal stability and unique structural properties. Its mode of action involves facilitating pyrolytic reactions by providing active sites that enhance the breakdown of complex organic molecules into simpler compounds. This catalytic activity is primarily due to its porous structure and acid-base active centers, which promote efficient molecular interactions during thermal decomposition.

Ravoxertinib hydrochloride is an investigational pharmaceutical compound, specifically a selective small molecule inhibitor. It is synthesized chemically, designed to target and inhibit specific protein kinases, particularly those associated with the ERK signaling pathway. The mode of action involves binding to these kinases, thus preventing their phosphorylation and subsequent activation. This interruption of the cellular signaling cascade can result in the suppression of tumor cell proliferation and survival.

FSL-1 is an advanced antimicrobial agent, which is derived from fatty acids and modified through a synthesis process involving surface-active molecules. This compound exhibits enhanced antimicrobial efficacy through its unique mode of action that disrupts microbial cell membranes by integrating into the lipid bilayer, causing structural instability and leakage of cellular contents. Such action effectively eliminates a broad spectrum of bacteria and fungi.

PKS21004 is a bioactive compound, specifically a secondary metabolite, which is derived from marine bacteria. This compound is produced through polyketide synthase pathways, typical of many bioactive natural products sourced from marine organisms. Its mode of action involves the inhibition of key cellular pathways critical for cancer cell proliferation and metastasis.

TT 232 is an advanced semiconductor characterization instrument, which is a critical tool in the field of materials science and electrical engineering. This product is sourced from the latest innovations in semiconductor technology, designed to provide comprehensive analysis of material properties. With a sophisticated mode of action, TT 232 employs high-resolution electrical measurements to assess parameters such as carrier concentration, mobility, and defect levels within semiconductor materials.

Inhibitor of HMG-CoA reductase

(E)-N-[(2S)-1-[5-[2-(4-Cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide is a novel small molecule, which is a synthetic compound designed for research purposes. Its structure is derived from a combination of pyrimidine and aniline derivatives, engineered to enhance biological activity and specificity. This compound functions mainly as a kinase inhibitor, targeting specific signaling pathways involved in cellular proliferation and survival. By inhibiting kinase activity, it can modulate aberrant signal transduction pathways frequently observed in various pathological conditions, including cancers.

PCI-33380 is a small molecule inhibitor, which is a synthetic compound specifically designed to target and inhibit the mammalian target of rapamycin (mTOR) pathway. This pathway plays a critical role in cell growth, proliferation, and survival by sensing and integrating various environmental cues. Inhibition of mTOR using compounds like PCI-33380 disrupts these signaling cascades, affecting tumor progression and providing a potentially effective approach for cancer therapeutics.

AZ82 is a small molecule inhibitor, which is synthetically derived, specifically targeting epigenetic regulatory pathways. It functions by inhibiting the activity of a particular class of enzymes involved in chromatin modification, thereby affecting gene expression patterns. Through its ability to modulate these epigenetic marks, AZ82 is instrumental in shifting transcriptional landscapes within cells.

Dichlorodenafil is a synthetic compound, which is an analogue of sildenafil. The source of this product is a laboratory synthesis where chemical manipulation replicates the structural characteristics of known phosphodiesterase inhibitors. Its mode of action involves the inhibition of the phosphodiesterase type 5 (PDE5) enzyme, leading to the relaxation of smooth muscle tissue and increased blood flow, primarily in the corpus cavernosum. This mechanism is similar to other compounds aimed at treating erectile dysfunction.

Agn 192403 hydrochloride is a synthetic compound designed as a selective antagonist of the calcitonin gene-related peptide (CGRP) receptor. This product is derived through chemical synthesis, specific to modulating biological pathways related to bone metabolism. Its mode of action involves inhibiting the activity of CGRP, a neuropeptide that plays a significant role in the regulation of bone resorption and vasodilation.

Rimtuzalcap is a monoclonal antibody, which is derived from a hybridoma technology involving the fusion of specific immune cells. It operates through the highly specific binding to a targeted antigen, thereby modulating immune responses or interfering with signaling pathways. This precision in action enhances its efficacy and minimizes off-target effects compared to broader immunomodulatory agents.

Tubulin binding agent; targets tumour vasculature

(2R)-2-Amino-3-(benzenesulfonylsulfanyl)propanoic acid is a synthetic compound characterized as a modified amino acid derivative. This product is derived from a sulfonylation process integrating the benzenesulfonyl moiety with a thiol group, resulting in a compound that also retains the structural features of an amino acid.

[Des-Arg9]-bradykinin acetate is a synthetic peptide, which is derived from bradykinin, a naturally occurring peptide in the body that acts as a mediator of various physiological processes. This compound is specifically modified by the removal of the C-terminal arginine residue, which alters its reactivity and affinity for certain receptors. It primarily acts on B1 receptors, which are upregulated in tissues under inflammatory conditions. By specifically targeting these receptors, [Des-Arg9]-bradykinin acetate serves as a valuable tool for exploring the roles of bradykinin in inflammation and pain pathways.